Resource Center
Always with a focus on innovation, find resources that share our scientific experts passion and knowledge. Find case studies, info sheets, posters and more.
Case Study: YourChoice Therapeutics
Download91 - 96 of 241 results
A First-in-Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor
24 March 2022A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
15 March 2022Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study
15 March 2022ACCP: A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
7 March 2022Astrazeneca - Characterization of Clinical ADME & Pharmacokinetics of Velsecorat Using an IV Microtracer Combined with an Inhaled Dose in Healthy Subjects
2 February 2022Development of a Once‑Daily Modified‑Release Formulation for the Short Half‑Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
10 January 2022Learn about Quotient Sciences' services
Where integrated CRDMO services bring therapies to life. Whether it's meeting your first-in-human milestone, confidently advancing your program to proof-of-concept, or providing a trusted supply of clinical trial materials or commercial drug product, learn about Quotient Sciences CRDMO offering and how we can support your next drug program.